Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022

被引：0
|
作者：
Kamat, Samir [1 ]
Ungar, Benjamin [2 ]
Agarwal, Aneesh [1 ]
Wan, Joy [3 ]
Ross, Joseph S. [4 ]
Gupta, Ravi [5 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[3] Johns Hopkins Univ, Dept Dermatol, Sch Med, Baltimore, MD USA
[4] Yale Sch Med, Dept Internal Med, Sect Gen Internal Med, New Haven, CT USA
[5] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA
来源：
JAMA DERMATOLOGY | 2024年 / 160卷 / 02期
关键词：
D O I：
10.1001/jamadermatol.2023.5036
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.
引用
收藏
页码：226 / 229
页数：4
相关论文
共 50 条
  • [21] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
    Molto, Consolacion
    Hwang, Thomas J.
    Borrell, Maria
    Andres, Marta
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau, Ariadna
    [J]. CANCER, 2020, 126 (19) : 4390 - 4399
  • [22] Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
    Sang, Angela
    Zhuo, Selena
    Bochanis, Adara
    Manautou, Jose E.
    Bahal, Raman
    Zhong, Xiao-bo
    Rasmussen, Theodore P.
    [J]. BIODRUGS, 2024, 38 (04) : 511 - 526
  • [23] A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration
    He, Qian
    Li, Qiu
    Lv, Fanzhen
    Kaitin, Kenneth I.
    Shao, Liming
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (04) : 676 - 684
  • [24] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Cherny, Nathan I.
    Dafni, Urani
    Bogaerts, Jan
    Latino, Nicola J.
    Pentheroudakis, George
    Douillard, Jean-Yves
    Tabernero, Josep
    Zielinski, Christoph
    Piccart, Martine J.
    de Vries, Elisabeth G. E.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10)
  • [25] Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    [J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 383 - 383
  • [26] A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration
    Qian He
    Qiu Li
    Fanzhen Lv
    Kenneth I. Kaitin
    Liming Shao
    [J]. Therapeutic Innovation & Regulatory Science, 2021, 55 : 676 - 684
  • [27] DRUGS APPROVED FOR CLINICAL USE BY FOOD AND DRUG ADMINISTRATION
    DEHAEN, P
    [J]. JOURNAL OF NEW DRUGS, 1965, 5 (06): : 358 - &
  • [28] DRUGS APPROVED FOR CLINICAL USE BY FOOD AND DRUG ADMINISTRATION
    DEHAEN, P
    [J]. JOURNAL OF NEW DRUGS, 1966, 6 (02): : 112 - &
  • [29] Update on Novel Drugs for Primary Care Practice: Drugs Approved by the US Food and Drug Administration in 2015
    Smetana, Gerald W.
    [J]. ANNALS OF INTERNAL MEDICINE, 2016, 164 (09) : W48 - W54
  • [30] Transparency and Dermatologic Device Approval by the US Food and Drug Administration
    Ezaldein, Harib H.
    Scott, Jeffrey F.
    Yin, Emily S.
    Ventura, Alessandra
    DeRuyter, Nicholaas P.
    Leffell, David J.
    [J]. JAMA DERMATOLOGY, 2018, 154 (03) : 273 - 280
12345